Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Net Income (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Net Income for 6 consecutive years, with -$29.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 23.11% to -$29.4 million in Q3 2025 year-over-year; TTM through Dec 2025 was -$77.0 million, a 53.8% increase, with the full-year FY2025 number at -$148.1 million, up 0.66% from a year prior.
  • Net Income was -$29.4 million for Q3 2025 at Caribou Biosciences, up from -$47.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$13.2 million in Q1 2021 to a low of -$47.6 million in Q2 2025.
  • A 5-year average of -$29.6 million and a median of -$30.0 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 664.48% in 2021, then surged 44.86% in 2023.
  • Caribou Biosciences' Net Income stood at -$18.5 million in 2021, then crashed by 65.47% to -$30.6 million in 2022, then dropped by 22.45% to -$37.4 million in 2023, then decreased by 3.83% to -$38.9 million in 2024, then grew by 24.37% to -$29.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Net Income are -$29.4 million (Q3 2025), -$47.6 million (Q2 2025), and -$38.9 million (Q4 2024).